Indian Journal of Dermatology
  Publication of IADVL, WB
  Official organ of AADV
Indexed with Science Citation Index (E) , Web of Science and PubMed
 
Users online: 2306  
Home About  Editorial Board  Current Issue Archives Online Early Coming Soon Guidelines Subscriptions  e-Alerts    Login  
    Small font sizeDefault font sizeIncrease font size Print this page Email this page


 
Table of Contents 
E-IJD CORRESPONDENCE
Year : 2017  |  Volume : 62  |  Issue : 4  |  Page : 441
Refractory psoriasis vulgaris with itching successfully treated with the anti-interleukin-17A antibody secukinumab: A case of secondary failure of other biologic agents


Department of Dermatology, Juntendo University Urayasu Hospital, Chiba, Japan

Date of Web Publication10-Jul-2017

Correspondence Address:
Yuko Kurosaki
Department of Dermatology, Juntendo University Urayasu Hospital, Chiba
Japan
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijd.IJD_97_17

Rights and Permissions



How to cite this article:
Kurosaki Y, Takamori K, Suga Y. Refractory psoriasis vulgaris with itching successfully treated with the anti-interleukin-17A antibody secukinumab: A case of secondary failure of other biologic agents. Indian J Dermatol 2017;62:441

How to cite this URL:
Kurosaki Y, Takamori K, Suga Y. Refractory psoriasis vulgaris with itching successfully treated with the anti-interleukin-17A antibody secukinumab: A case of secondary failure of other biologic agents. Indian J Dermatol [serial online] 2017 [cited 2020 Jul 9];62:441. Available from: http://www.e-ijd.org/text.asp?2017/62/4/441/210100


Sir,

A 60-year-old Japanese man with a 30-year history of psoriasis vulgaris was referred to our hospital. His previous treatments, including topical corticosteroids, Vitamin D analogs, narrowband ultraviolet B, and cyclosporine, demonstrated poor disease control. At his first visit, he presented with scaly erythematous plaques on his trunk, extremities, and scalp, with considerable itching. At the time, his Psoriasis Area and Severity Index (PASI) score was 37, with an itch Numeric Rating Scale (itch NRS) score was 6 [Figure 1]A.
Figure 1: (a-e) Follow-up photographs taken at the corresponding time points indicated in the graph (F). (A) Before biologic treatment; (B-D) after secondary failure of biologics. (F) Changes in the Psoriasis Area and Severity Index score (line graph) and itch Numeric Rating Scale (bar graph)

Click here to view


Treatment was started with a 45 mg ustekinumab subcutaneous injection, which inhibits interleukin (IL)-12/23; it was initially effective against both psoriatic lesions and pruritus. However, clinical responsiveness was lost after 64 weeks [Figure 1]B. His dose was then doubled to 90 mg, but the skin condition did not improve.

Owing to the secondary failure with ustekinumab, it was switched to the tumor necrosis factor (TNF)-α inhibitor, adalimumab. Initially, an 80 mg subcutaneous injection was administered, followed by a 40 mg dose every other week. He showed no significant improvement with this regimen, and subsequently developed shoulder arthritis with psoriatic pruritus after 20 weeks, even after doubling the dose to 80 mg [Figure 1]C.

To treat the symptom, a combination of another TNF-α inhibitor, infliximab (5 mg/kg, intravenous), and oral methotrexate (4 mg once weekly) was administered. Thereafter, arthralgia quickly resolved after 4 weeks, but headache and dyspnea developed during the seventh infusion of infliximab. Therefore, the treatment was discontinued [Figure 1]D.

Finally, treatment was switched to secukinumab, which selectively targets IL-17A. Before the secukinumab treatment, the patient's PASI score was 18, with an itch NRS score of 3. Following the five initial subcutaneous secukinumab injections, his itch dissipated while the PASI score significantly dropped to 7. After 32 weeks, PASI 100 (clear skin) was achieved. The patient's condition is currently well controlled without arthralgia or pruritus, even after 64 weeks of receiving secukinumab [Figure 1]E.

Our patient showed refractory psoriasis, which became unresponsive to several biologics. Antibodies against ustekinumab, adalimumab, and infliximab were reported in 3.8%–6%, 6%–45%, and 5.4%–43.6% of psoriasis patients, respectively.[1] Only 0.4% of patients developed anti- secukinumab antibodies over 52 weeks.[2] Further, secukinumab and ustekinumab resulted in lower numbers of T-cell epitopes and lower T-cell response rates in humans, than did adalimumab and infliximab,[3] indicating that secukinumab has a low immunogenic potential and is well tolerated.

Pruritus affects about 60%–90% psoriasis patients.[4] Recent studies have pointed to the important role of biologic agents in itch intensity reduction in participants suffering from psoriasis.[5] The correlation between PASI score and itch NRS is notable in the present case [Figure 1]F. Itching recurred when psoriasis started to flare because of poor responses to biologics. Therefore, psoriatic itch may be related to abnormal functioning of cytokines in the IL-12/23, TNF-α, and IL-17A pathways in psoriasis.

In conclusion, targeting IL-17A appears to be effective against psoriasis vulgaris with persistent pruritus, in patients with a history of secondary failure of other biologics.

Acknowledgment

We are grateful to Dr. Osamu Negi, Dr. Utako Kimura, and Dr. Kaori Takeuchi of Department of Dermatology, Juntendo University Urayasu Hospital, Chiba, Japan, for their clinical assistance for following up of the patient.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
   References Top

1.
Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis: A systematic review. Br J Dermatol 2014;170:261-73.  Back to cited text no. 1
[PUBMED]    
2.
Reich K, Blauvelt A, Armstrong A, Langley RG, Fox T, Huang J, et al. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2017;176:752-8.  Back to cited text no. 2
[PUBMED]    
3.
Karle A, Spindeldreher S, Kolbinger F. Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity. MAbs 2016;8:536-50.  Back to cited text no. 3
[PUBMED]    
4.
Szepietowski JC, Reich A. Pruritus in psoriasis: An update. Eur J Pain 2016;20:41-6.  Back to cited text no. 4
[PUBMED]    
5.
Szepietowski JC, Reich A. Itch in psoriasis management. Curr Probl Dermatol 2016;50:102-10.  Back to cited text no. 5
[PUBMED]    


    Figures

  [Figure 1]



 

Top
Print this article  Email this article
 
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (476 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    References
    Article Figures

 Article Access Statistics
    Viewed1712    
    Printed26    
    Emailed0    
    PDF Downloaded58    
    Comments [Add]    

Recommend this journal